AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$OSUR

OraSure: Q3 Earnings Snapshot

OraSure Technologies (OSUR) reported a Q3 loss of $13.1M, or 19 cents per share. Adjusted losses were 15 cents per share. Revenue was $30.9M. The company expects Q4 revenue between $30M and $32M.

Original reporting
finance.yahoo.com
Published Nov 9, 2026, 10:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
OraSure: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$OSURBearishMed
01

Why it matters

The earnings miss and lowered guidance suggest short‑term weakness, but the company's long‑term growth prospects remain tied to public health trends.

02

Market read

First‑report earnings release for a micro‑cap; likely to move the stock modestly.

03

What to watch

Potential upcoming contracts or regulatory approvals not disclosed in this brief could mitigate the downside.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

OraSure Technologies (OSUR) is a provider of rapid diagnostic tests, primarily for infectious diseases.

Company-level read

Ticker impact

$OSURBearishHigh confidence
Context

OraSure Technologies reported a Q3 loss of $13.1M and lowered Q4 revenue guidance to $30M-$32M.

Expected impact

downside pressure as investors price in the loss and lower outlook

Evidence & confidence

The company posted a loss and cut guidance, which historically triggers sell‑offs for small‑cap stocks.

Market effects

Sector

Diagnostic test sector may see modest pullback as a peer reports weaker results.

Regional

Limited to U.S. small‑cap investors.

Global

Low; impact confined to OraSure and its niche market.

Counterpoint

What could challenge this read

If the market overreacts, a bounce could occur on the back of long‑term demand for diagnostic testing.

Key entities

  • company
    OraSure Technologies Inc.

    Diagnostic test maker reporting Q3 results.

Read at source← All news

Also covered by

1 outlet

Related articles

$OSURMed

OraSure Technologies Q3 Earnings Call Highlights

OraSure (NASDAQ:OSUR) reported a Q3 GAAP operating loss of $13M and non-GAAP loss of $10.2M. It forecasts Q4 revenue of $30M-$32M, up 12-20% YoY. The company expects full-year revenue growth to accelerate in 2027. OraSure has launched its Ebola 2.0 rapid antigen test and Colli-Pee Dx urine collection kit, with initial sales encouraging. It is working on FDA pre-submission for its InteliQuick CT/NG molecular self-test.

finance.yahoo.com
$OSURMed

OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion

ORASURE TECHNOLOGIES INC (OSUR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Investor Contact: Media Contact: Mike Vallie Amy Koch investorinfo@orasure.com media@orasure.com OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion • 14% year-over-year revenue gr

SEC EDGAR 8-K
$OSURMed

OraSure (OSUR) Returns To Profit, But Growth Remains Elusive

OraSure (OSUR) reported Q2 2026 GAAP net income of $6.2M, reversing a $19.7M loss from a year earlier. Revenue rose 9.7% quarter-over-quarter to $30.6M, beating guidance. Gross margins improved, and diagnostics revenue grew 1% YoY. The profit was largely due to a $22.6M accounting adjustment, with underlying losses widening. The company secured two FDA clearances but delayed a product submission. Hedge fund ownership increased, and short interest is 4.79%.

insidermonkey.com
$OSURMedAI 8/10

OraSure (OSUR) Q2 2026 Earnings Call Transcript

OraSure Technologies (OSUR) reported Q2 2026 revenue of $30.6M, up 9.7% sequentially, including $19.4M Diagnostics revenue and $9.9M Sample Management Solutions revenue. GAAP gross margin was 43.5% and GAAP operating income $5.4M. Q3 revenue guidance is $29.5M to $32.5M. Management said FDA clearance for Colli-Pee and EUA for OraQuick Ebola 2.0 were received, while IntelliQ CT/NG submission was withdrawn.

fool.com
$OSURMed

OraSure Announces Second Quarter 2026 Financial Results

ORASURE TECHNOLOGIES INC (OSUR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Investor Contact: Media Contact: investorinfo@orasure.com media@orasure.com OraSure Announces Second Quarter 2026 Financial Results BETHLEHEM, PA, August 5, 2026 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnost

SEC EDGAR 8-K
$OSURMedAI 8/10

OraSure receives Emergency Use Authorization for second generation Ebola test

OraSure Technologies said the U.S. FDA granted Emergency Use Authorization for its second generation OraQuick Ebola 2.0 Rapid Antigen Test. The single-use test detects four Ebola virus types and can use blood or oral fluids. OraSure cited improved sensitivity, longer shelf life, and automated manufacturing, and plans to ramp production. The DRC and Uganda outbreak has 2,473 cases and 999 deaths, per Congo’s Ministry of Health.

wfmz.com